A Retrospective Case Series Review of the Peroxisome Proliferator-Activated Receptor Ligand Rosiglitazone in the Treatment of Atopic Dermatitis
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that are expressed in a variety of cells, including keratinocytes and cells of the immune system. The gamma subtype, activated by the antidiabetic thiazolidinediones, was originally identified as a regulator of adipogenesis and glucose homeostasis. Recent data, however, have linked PPAR-gamma to several genes involved in inflammation. Among others, these pathways reduce certain inflammatory mediators in the skin and regulate epidermal barrier homeostasis, alterations of which contribute to the inflammation associated with atopic dermatitis (AD). To our knowledge, the addition of rosiglitazone maleate to the standard treatment of AD has not been evaluated. OBSERVATIONS: Severe adverse events were not observed, although 1 patient experienced weight gain. All patients responded to rosiglitazone therapy with decreased total body surface area involvement, severity of lesions, and number of flares. CONCLUSIONS: Rosiglitazone, a drug that has an excellent safety profile, may offer a well tolerated systemic treatment option for AD. However, its role should be further assessed in controlled trials to establish its efficacy and safety in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palmer, C. N. A., Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P., Goudie, D. R., Sandilands, A., Campbell, L. E., Smith, F. J. D., et al. (2006) · Nature Genetics · doi:10.1038/ng1767 · Cited by 2,978 · cited 13×
“As a result, rosiglitazone may serve as a good alternative to current systemic immunosuppressants used for severe AD.”
BackgroundInfluentialNew insights into atopic dermatitis
Leung, D. Y. M., Boguniewicz, M., Howell, M. D., Nomura, I., & Hamid, Q. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21060 · Cited by 1,435
Epidemiology of atopic dermatitis
Larsen, F. S., & Hanifin, J. M. (2002) · Immunology and Allergy Clinics of North America · doi:10.1016/s0889-8561(03)00066-3 · Cited by 310 · cited 1×
“A TOPIC DERMATITIS (AD) IS a common inflammatory skin disease with a lifetime prevalence of 10% to 20% in children and 1% to 3% in adults.(1) The disease displays a relapsing course that can lead to considerable morbidity, social isolation, and emotional stress.”
Background
Cited by
Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation
Schmuth, M., Moosbrugger-Martinz, V., Blunder, S., & Dubrac, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.11.012 · Cited by 100
Ghosh, D., Ding, L., Sivaprasad, U., Geh, E., Biagini Myers, J., Bernstein, J. A., Khurana Hershey, G. K., & Mersha, T. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0144316 · Cited by 94
Metadata
- Authors
- Behshad, R., Cooper, K. D., & Korman, N. J.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2008-01-01
- Volume
- 144
- Issue
- 1
- Pages
- 84-8
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W1972525283
- Cited by
- 51
- References
- 3
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Retrospective Case Series Review of the Peroxisome Proliferator-Activated Receptor Ligand Rosiglitazone in the Treatment of Atopic Dermatitis. https://app.cochat.ai/papers/10.1001/archdermatol.2007.22
- The paper
- Behshad, R., Cooper, K. D., & Korman, N. J. (2008). A Retrospective Case Series Review of the Peroxisome Proliferator-Activated Receptor Ligand Rosiglitazone in the Treatment of Atopic Dermatitis. Archives of Dermatology. https://doi.org/10.1001/archdermatol.2007.22
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.